Here, we evaluate CD13 expression and its prognostic impact in human NSCLC, as well as demonstrate in vivo therapeutic activity of tTF-NGR against CD13+ tumor NSCLC xenografts. This evidence concerns the gene ANPEP and non-small cell lung carcinoma.